The effectiveness of the complement inhibition therapies at the C3 level (compstatin) and C5 level (RA101295), along with CD14 inhibition monotherapy were already proven to be beneficial in porcine and baboon sepsis models (39–43). This evidence concerns the gene C3 and Sepsis.